Based on the Chinese anti-TB treatment cohort, we did not find a statistically significant association between genetic polymorphisms of CYP2E1 and the risk of anti-TB drug-induced hepatitis. This evidence concerns the gene CYP2E1 and hepatitis A virus infection.